Last updated: September 18, 2026
TICLID is the former brand name for ticlopidine hydrochloride, an oral antiplatelet drug. Its commercial decline resulted from safety risks, the displacement of ticlopidine by clopidogrel, generic competition, and the absence of meaningful remaining exclusivity. TICLID has no material branded market in the United States, and publicly available filings do not identify a current standalone revenue stream for the product.
What is TICLID and how was it used?
TICLID contains ticlopidine hydrochloride, a thienopyridine antiplatelet agent that inhibits ADP-mediated platelet aggregation. The drug was approved in the United States for reducing the risk of thrombotic stroke in patients with a prior thrombotic stroke or in patients unable to tolerate or benefit from aspirin. It was also approved as an adjunct to coronary stent implantation to reduce the risk of stent thrombosis (U.S. Food and Drug Administration [FDA], 1998).
Ticlopidine is a prodrug. Its active metabolites irreversibly inhibit the platelet P2Y12 receptor, producing an antiplatelet effect that persists for the life of the platelet. The pharmacology later became the basis for the commercial success of clopidogrel, which offered a more favorable safety and tolerability profile.
Key product facts
| Category |
TICLID |
| Active ingredient |
Ticlopidine hydrochloride |
| Drug class |
Thienopyridine P2Y12 platelet inhibitor |
| Original brand holder |
Roche |
| U.S. dosage form |
250 mg oral tablet |
| Initial U.S. approval |
Early 1990s |
| Primary historical uses |
Secondary stroke prevention; coronary stent thrombosis prevention |
| FDA regulatory category |
Small-molecule prescription drug |
| Current U.S. branded position |
No meaningful commercial presence |
| Biosimilar relevance |
None |
| Main commercial successor |
Clopidogrel |
What FDA safety issues affected TICLID demand?
Safety concerns were the main structural weakness in the TICLID franchise. The FDA label carried boxed warnings for potentially fatal hematologic reactions, including thrombotic thrombocytopenic purpura, aplastic anemia, and neutropenia or agranulocytosis (FDA, 1998).
Ticlopidine required blood-count monitoring during initial treatment. The label recommended complete blood counts every two weeks during the first three months of therapy. That monitoring burden reduced physician and patient acceptance, particularly after safer alternatives became available.
Principal safety liabilities
| Risk |
Commercial effect |
| Thrombotic thrombocytopenic purpura |
Restricted prescribing and increased monitoring |
| Aplastic anemia |
Created a serious and sometimes fatal safety concern |
| Neutropenia and agranulocytosis |
Required repeated blood-count surveillance |
| Diarrhea and gastrointestinal intolerance |
Reduced adherence |
| Rash and other adverse effects |
Weakened patient acceptance |
| Delayed onset and offset of action |
Reduced procedural flexibility |
The safety profile did not eliminate all clinical utility. Ticlopidine remained an effective antiplatelet agent, but clinical effectiveness was insufficient to offset monitoring requirements and the availability of alternatives.
When did TICLID lose market exclusivity?
TICLID lost practical exclusivity many years ago. The original compound and product patents date from the early development period and have expired. No active U.S. patent estate appears to block generic ticlopidine hydrochloride tablets.
The relevant commercial sequence was:
| Period |
Market event |
| Early 1990s |
U.S. approval and launch of TICLID |
| Mid-1990s |
Safety warnings and monitoring requirements constrained adoption |
| 1997 |
FDA approval of Plavix, or clopidogrel bisulfate |
| Late 1990s to 2000s |
Clopidogrel displaced ticlopidine in most major uses |
| 2000s |
Generic ticlopidine became available |
| 2010s |
Branded TICLID lost practical commercial relevance |
| Current period |
Market consists primarily of limited generic or regional supply, where available |
The original TICLID commercial opportunity is therefore an expired-asset case rather than a pending exclusivity event. The key question is not when generic entry may occur. Generic entry has already occurred. The commercial question is whether any residual demand can support continued manufacturing.
What patents protect TICLID today?
No material live U.S. patent protection is associated with the original TICLID product. The principal patent categories relevant to ticlopidine were:
- The ticlopidine active compound.
- Pharmaceutical compositions containing ticlopidine hydrochloride.
- Tablet formulations.
- Methods of preventing thrombotic events.
- Manufacturing and purification processes.
These protections are historical rather than current commercial barriers. Any surviving patent rights in individual jurisdictions would need to be assessed on a country-by-country basis, but the U.S. market does not have a meaningful patent-based barrier to generic competition.
Patent-estate assessment
| Patent category |
Current commercial significance |
| Active ingredient |
Expired |
| Original tablet formulation |
Expired |
| Stroke-prevention methods |
Expired or commercially irrelevant |
| Coronary-stent use |
Expired or commercially irrelevant |
| Manufacturing processes |
Possible process-specific rights in some jurisdictions, but no known U.S. market block |
| Pediatric or regulatory exclusivity |
None of material current significance |
| Orange Book exclusivity |
No meaningful current exclusivity |
Ticlopidine is a small molecule, so biosimilar rules do not apply. Any competing product would proceed through an abbreviated new drug application or another small-molecule pathway, not through the biosimilar framework.
What is the Orange Book status of TICLID?
The Orange Book historically included ticlopidine hydrochloride tablets and generic abbreviated new drug applications. Current commercial availability can differ from Orange Book listing status because an approved product may not be actively marketed.
The practical U.S. regulatory position is:
- No meaningful new-drug exclusivity remains.
- No relevant pediatric exclusivity remains.
- No viable branded market position remains for TICLID.
- Generic approval, where active, is the principal regulatory route.
- Paragraph IV litigation is not a current commercial issue for the original brand.
FDA Orange Book listings should be distinguished from actual distribution. A product may retain an approved application while having limited or no commercial sales. That distinction matters for market sizing and supplier analysis (FDA, 2024).
Were there Paragraph IV challenges or patent lawsuits involving TICLID?
Ticlopidine was exposed to ordinary generic competition after the expiration of its historical patent protection, but it is not a current Paragraph IV litigation market.
A Paragraph IV certification challenges the validity, enforceability, or infringement of a listed patent before patent expiration. That mechanism has no current strategic significance for TICLID because the product’s commercial patent life has ended.
The litigation profile differs from newer antiplatelet products:
| Issue |
TICLID position |
| Active Orange Book patent dispute |
None of material current significance |
| Current Paragraph IV risk |
Minimal |
| Authorized generic strategy |
No significant branded strategy identified |
| Settlement agreements |
No commercially consequential current settlements identified |
| Product-liability exposure |
Historically more relevant than patent litigation |
| Regulatory enforcement risk |
Primarily tied to safety and manufacturing compliance |
Historical product-liability and safety concerns were more commercially important than patent litigation. The risk profile centered on hematologic toxicity, monitoring failures, and prescribing decisions.
How did clopidogrel change TICLID’s market?
Clopidogrel was the decisive competitive threat. It targeted the same broad P2Y12 antiplatelet pathway while offering a substantially more favorable clinical and operational profile.
TICLID versus clopidogrel
| Attribute |
TICLID |
Clopidogrel |
| Active ingredient |
Ticlopidine |
Clopidogrel |
| Drug class |
Thienopyridine |
Thienopyridine |
| Monitoring requirement |
Routine early blood-count monitoring |
No comparable routine hematologic monitoring requirement |
| Hematologic toxicity |
Major commercial concern |
Lower relative concern |
| Dosing convenience |
Twice daily in historical use |
Once daily |
| Initial market position |
Earlier entrant |
Later entrant |
| Current use |
Limited and declining |
Broad historical use, now generic |
| Commercial outcome |
Displaced |
Became the standard oral P2Y12 successor |
Clopidogrel did not merely compete on price. It reduced operational friction for physicians and patients. Hospitals and cardiologists had strong incentives to move away from a drug requiring blood-count surveillance when a once-daily alternative was available.
What was the financial trajectory of TICLID?
TICLID’s financial trajectory followed a classic rapid-decline pattern:
- Launch growth: Early adoption in stroke prevention and coronary intervention.
- Safety discount: Monitoring and serious blood dyscrasias limited peak penetration.
- Therapeutic substitution: Clopidogrel captured most new prescriptions.
- Generic erosion: Remaining sales moved from branded to low-price generic supply.
- Commercial tail: Demand persisted in narrow settings and selected countries.
- Near-zero branded revenue: The original brand ceased to represent a material pharmaceutical asset.
Roche did not generally report TICLID as a major standalone revenue line in public financial disclosures. Public company reporting usually grouped older products within broader cardiovascular or established-products categories. A reliable current TICLID revenue figure is therefore not available from audited company disclosures.
Financial trajectory by phase
| Phase |
Revenue condition |
Margin condition |
Strategic value |
| Initial launch |
Growing |
Branded margins |
High relative to development cost |
| Pre-clopidogrel maturity |
Meaningful but constrained |
Positive, reduced by safety management |
Moderate |
| Clopidogrel displacement |
Declining |
Compressed |
Low |
| Generic era |
Small residual sales |
Low |
Supply continuity only |
| Current state |
Immaterial at global branded level |
Commodity-like |
Limited licensing value |
The largest financial loss was not caused by one patent cliff. It came from substitution before the full generic erosion period. Clopidogrel reduced the addressable market for ticlopidine while TICLID still had nominal brand recognition.
What market dynamics affect generic ticlopidine?
The remaining market is governed by supply economics rather than innovation.
Demand-side factors
- Physicians generally prefer clopidogrel or newer P2Y12 inhibitors.
- Ticlopidine’s monitoring burden limits first-line use.
- Guidelines have reduced its role in routine antiplatelet treatment.
- Use may persist when alternatives are unsuitable, unavailable, or poorly tolerated.
- Historical familiarity may support small regional demand.
Supply-side factors
- Low volumes reduce manufacturing incentives.
- Generic manufacturers may discontinue products when margins fall below compliance and inventory costs.
- Active pharmaceutical ingredient supply is less strategically important than for high-volume cardiovascular drugs.
- Hospitals may face intermittent availability even where the product remains technically approved.
- Manufacturing changes can trigger regulatory work without a meaningful revenue opportunity.
Geographic coverage
Ticlopidine availability has become jurisdiction-specific. The product may remain registered or supplied in selected markets, but U.S. commercial relevance is limited. Global demand is likely concentrated in countries where legacy prescribing, local registration, or access constraints sustain use.
A country-level assessment should separate four conditions:
- Registered but not marketed.
- Approved and intermittently supplied.
- Actively marketed as a generic.
- Replaced by other antiplatelet products.
What generic launch risks exist for TICLID?
Generic launch risk is low because the drug is already off-patent. The main risks are commercial, regulatory, and manufacturing rather than legal.
| Risk type |
Assessment |
| Patent infringement |
Low |
| Paragraph IV challenge |
Low |
| Regulatory approval |
Standard generic pathway |
| Product liability |
Elevated relative to newer antiplatelet products because of known hematologic risks |
| Market size |
Very small |
| Price erosion |
Severe |
| Supply interruption |
Meaningful |
| Reimbursement support |
Limited |
| Competitive substitution |
High |
A new entrant would need a clear supply or access rationale. Patent exclusivity would not provide a commercial moat. The likely launch strategy would be low-cost supply to institutional or niche markets rather than broad physician promotion.
How strong is the TICLID patent estate?
The current patent estate is weak from a business perspective. Historical compound, formulation, and use patents no longer create meaningful exclusivity in the United States. The product’s remaining defensibility rests on manufacturing know-how, regulatory maintenance, supply reliability, and local market access.
Commercial patent-strength scorecard
| Factor |
Assessment |
| Composition-of-matter protection |
Exhausted |
| Formulation protection |
Exhausted |
| Method-of-use protection |
Exhausted or nonblocking |
| Regulatory exclusivity |
None of material significance |
| Manufacturing differentiation |
Limited |
| Brand recognition |
Historical only |
| Barriers to generic entry |
Low |
| Licensing attractiveness |
Low |
The asset could have limited value in a portfolio focused on legacy medicines, emerging-market supply, or hospital procurement. It has little value as a conventional branded pharmaceutical franchise.
What is the outlook for TICLID revenue?
The outlook is stable at a very low base or declining further, depending on regional availability. There is no credible path to a material U.S. revenue recovery without a major change in clinical practice, and such a change is unlikely given the availability of clopidogrel and newer antiplatelet agents.
Potential residual revenue sources include:
- Countries with continued generic demand.
- Patients unable to use alternative P2Y12 inhibitors.
- Institutional contracts requiring legacy products.
- Temporary shortages of substitute antiplatelet drugs.
- Markets with limited access to newer therapies.
These sources are insufficient to restore the product to branded blockbuster status. The more realistic commercial scenario is a fragmented generic tail with periodic discontinuations.
Key Takeaways
- TICLID is ticlopidine hydrochloride, an older oral P2Y12 antiplatelet drug.
- Its principal commercial weaknesses were thrombotic thrombocytopenic purpura, aplastic anemia, neutropenia, gastrointestinal intolerance, and mandatory early blood-count monitoring.
- Clopidogrel displaced TICLID before generic competition fully eroded the brand.
- Historical U.S. compound, formulation, and use patents have expired.
- TICLID has no material current FDA exclusivity or Paragraph IV litigation profile.
- Biosimilar risk is irrelevant because ticlopidine is a small molecule.
- Current market value is concentrated in limited generic or regional supply.
- Public filings do not provide a reliable standalone current revenue figure.
- The principal risks are low demand, price erosion, discontinuation, safety liability, and supply fragmentation.
- TICLID has low licensing value except in niche legacy-product or access-constrained markets.
FAQs About TICLID Market and Patent Status
Is TICLID still available in the United States?
Ticlopidine hydrochloride may remain listed through generic regulatory channels, but TICLID has no meaningful branded U.S. market presence. Actual availability depends on current manufacturer distribution and pharmacy supply.
Is ticlopidine stronger than clopidogrel?
Ticlopidine is an effective antiplatelet agent, but its safety and monitoring profile is less favorable than clopidogrel’s. Clopidogrel became the preferred successor because it offers once-daily dosing without the same routine early blood-count monitoring burden.
Does TICLID have an active composition-of-matter patent?
No material active U.S. composition-of-matter patent protects the original ticlopidine product. The relevant historical patent term has expired.
Can a generic company obtain market exclusivity for ticlopidine?
A new generic entrant would not normally obtain meaningful market exclusivity merely by launching ticlopidine. The product is an established off-patent small molecule, and commercial differentiation would depend on supply, pricing, registration, and distribution.
Why did TICLID decline despite being clinically effective?
TICLID declined because clinical efficacy did not offset serious hematologic risks, routine monitoring requirements, tolerability problems, and the arrival of clopidogrel. Generic price erosion then eliminated most remaining branded economics.
References
-
U.S. Food and Drug Administration. (1998). Ticlid (ticlopidine hydrochloride) tablets: Prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
National Library of Medicine. (2024). Ticlopidine hydrochloride. DailyMed.
-
National Center for Biotechnology Information. (2024). Ticlopidine. PubChem Compound Summary. National Library of Medicine.
-
CAPRIE Steering Committee. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. The Lancet, 348(9038), 1329-1339.
